Celularity, Inc. (“Celularity”), a clinical-stage cell therapeutics company focused on the development of innovative allogeneic cellular therapies derived from post partum human placentas, announced data introducing an extensive platform in genetically-modified NK- and T cell-based programs, and highlighting long-term safety and efficacy results from the Phase 1 study of PNK-007 in patients with multiple myeloma (MM). These data were announced at the 61st American Society of Hematology (ASH) Annual Meeting in Orlando, F.L.
Celularity, Inc. (“Celularity” ), a clinical-stage cell therapeutics company focused on the development of innovative allogeneic cellular therapies from human placentas, today announced pre-clinical data supporting the advancement of CYNK-001, a placental-derived, cryopreserved natural killer (NK) cell therapy, as a clinical candidate for patients with glioblastoma multiforme (GBM) in a poster presentation at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting in Phoenix, A.Z.
Five abstracts to be presented on the pre-clinical and clinical results, demonstrating the breadth and versatility of the Company’s allogeneic, off the shelf, placental derived cell therapy platform in multiple myeloma and lymphoma
Celularity, Inc. (“Celularity” or the “Company”), a clinical-stage cell therapeutics company developing allogeneic cellular therapies harnessed from human placentas, today announced the Company has entered into a long-term lease agreement to develop a 145,000 square-foot advanced cell manufacturing and research facility in Florham Park, New Jersey. Celularity will relocate its corporate headquarters to the new facility when it opens in early 2020.
First-ever Results to be Presented from Multiple Studies Evaluating Company’s PNK Allogeneic Cell Therapy in Patients with Acute Myeloid Leukemia and Multiple Myeloma
Celularity, Inc., a clinical-stage cell therapeutics company developing allogeneic cellular therapies harnessed from human placentas, today announced it will present first-ever clinical and pre-clinical results from its comprehensive placental hematopoietic stem cell derived natural killer (PNK) cells oncology program at the 2019 American Association for Cancer Research (AACR) Annual Meeting being held from March 29 – April 3, 2019 in Atlanta, Georgia.
Celularity Presents Pre-Clinical and Clinical Data from its Allogeneic, Placental-Derived, Off-the-Shelf Cell Therapy Platform at the 2019 ASH Annual Meeting
Celularity Presents Pre-Clinical Data Demonstrating the Potential of Allogeneic Placental-Derived, Cryopreserved NK Cell Therapy (CYNK-001) in Glioblastoma at the 2019 Society for Neuro-Oncology Annual Meeting
Celularity to Present New Data at the ASH Annual Meeting on Novel Allogeneic, Off the Shelf, Placental Derived CAR T and NK Cell Therapy Programs
Celularity Enters Lease to Develop Advanced Cell Manufacturing and Research Facility for Commercial-Scale Placental-Derived Allogeneic Cell Therapies
Celularity Announces Results of Phase 1 Studies of PNK-007, an Allogeneic, Off-the-Shelf, Placental-Derived Cell Therapy, at AACR Annual Meeting 2019
First Clinical Results Evaluating Allogeneic, Off-The-Shelf, Placental-Derived Cells to be Presented by Celularity at 2019 AACR Annual Meeting